Read the reports from the American Association of Diabetes Educators National Conference 2019 in
Houston, TX (August 9-12)

< Back to Press

1 March 2022


Parsippany, United States

Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the Eversense® NOW Remote Monitoring App for the Android Operating System in Europe. With this launch, remote monitoring capabilities are now available for all Eversense® and Eversense® XL Continuous Glucose Monitoring (CGM) users on Android and iOS operating systems in the US and Europe, respectively.

Developed by Senseonics and brought to people with diabetes by Ascensia, Eversense is the world’s first and only long-term continuous glucose monitoring system. The Eversense NOW Remote Monitoring App allows real-time glucose data and alerts from Eversense users to be remotely shared with friends and family. The app allows up to five people to remotely receive updated readings approximately every five minutes, with the ability to easily view recent trends and alerts.

“The value of remote monitoring in healthcare has never been clearer than in the last two years, with tools providing added peace of mind for users and their support system,” said Elaine Anderson, Head of Senseonics CGM Business Unit at Ascensia Diabetes Care. “Managing diabetes requires continuous monitoring and decision making, and this app makes it easier for friends and family to be part of that process. Having a well-informed support network can reduce the burden placed on people with diabetes and we are excited to bring this useful tool to all Eversense users in Europe.”

The Eversense NOW Remote Monitoring App is now available for both Apple and Android devices across Europe and can be downloaded via the Apple® App Store and Google Play™ Store.


Notes for Editors

About Eversense

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 6 months in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a trained and certified health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.

For important safety information, see

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® continuous glucose monitoring systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation (formerly Panasonic Healthcare). Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at:

©2022 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. The Bluetooth® wordmark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license. Google Play and the Google Play logo are trademarks of Google LLC. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

For more media enquiries, please contact:

Tim Stamper,